03:39 AM EST, 01/21/2025 (MT Newswires) -- Nanobiotix ( NBTX ) said Tuesday it dosed the first patient in a phase 2 trial testing the experimental drug, JNJ-1900, for stage 3 non-small cell lung cancer.
The study is sponsored by Johnson & Johnson's ( JNJ ) subsidiary, Janssen Pharmaceutical, under a global licensing agreement.